Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.

Background: This multicenter study investigated the predictive value of baseline AFP and on-treatment AFP response for survival in hepatocellular carcinoma (HCC) patients with regorafenib. Materials & methods: A total of 578 patients with HCC treated with regorafenib from 12 institutions in South Korea and Italy were included. Baseline AFP (cutoff, 400 ng/ml) and AFP response (20% reduction from baseline) were analyzed for overall survival (OS) and progression-free survival (PFS). Results: Baseline AFP below 400 ng/ml was a significant factor that was independently associated with longer OS and PFS. AFP response was also a significant factor independently associated with longer OS and PFS. Conclusion: Baseline AFP and AFP response may be used as prognostic factors for survival in HCC treated with regorafenib.

[1]  Ming‐Lung Yu,et al.  Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels , 2021, Cancer medicine.

[2]  Myung Ah Lee,et al.  Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  M. Kudo,et al.  Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial , 2019, Annals of Oncology.

[4]  M. Imamura,et al.  Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib , 2019, Oncology.

[5]  N. Sugiura,et al.  Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan , 2019, Investigational New Drugs.

[6]  Su Jin Lee,et al.  Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma , 2018, Investigational New Drugs.

[7]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[8]  N. Rungsakulkij,et al.  Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection , 2018, World journal of clinical cases.

[9]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[10]  Ping Chen,et al.  The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma , 2017, Scientific Reports.

[11]  T. Gamblin,et al.  The prognostic utility of baseline alpha‐fetoprotein for hepatocellular carcinoma patients , 2017, Journal of surgical oncology.

[12]  A. Santoro,et al.  Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. , 2012, Journal of hepatology.

[13]  S. Fan,et al.  The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. , 2011, The oncologist.

[14]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[15]  Chih-Hung Hsu,et al.  Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma , 2010, Cancer.